Brokerages Give Average Rating of “Strong Buy” to Zogenix (NASDAQ:ZGNX)
March 29th, 2015 - 0 comments - Filed Under - by Jennifer Langley
Shares of Zogenix (NASDAQ:ZGNX) have been given a consensus broker rating score of 1.40 (Strong Buy) from the five brokers that cover the stock, Zacks Investment Research reports. One research analyst has rated the stock with a hold recommendation and four have given a strong buy recommendation to the company. Zogenix’s rating score has declined by 40% in the last 90 days as a result of a number of analysts’ ratings changes.
Brokerages have set a 1-year consensus target price of $2.75 for the company and are expecting that the company will post ($0.14) EPS for the current quarter, according to Zacks. Zacks has also assigned Zogenix an industry rank of 92 out of 265 based on the ratings given to related companies.
Zogenix (NASDAQ:ZGNX) opened at 1.34 on Thursday. Zogenix has a one year low of $1.07 and a one year high of $3.10. The stock has a 50-day moving average of $1. and a 200-day moving average of $1.. The company has a market cap of $205.51 million and a P/E ratio of 22.33.
Zogenix (NASDAQ:ZGNX) last announced its earnings results on Tuesday, March 10th. The company reported ($0.13) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.11) by $0.02. The company had revenue of $14.90 million for the quarter. During the same quarter in the prior year, the company posted ($0.13) earnings per share. The company’s quarterly revenue was up 50.5% on a year-over-year basis. On average, analysts predict that Zogenix will post $-0.37 earnings per share for the current fiscal year.
A number of analysts have recently weighed in on ZGNX shares. Analysts at William Blair downgraded shares of Zogenix from an “outperform” rating to a “market perform” rating in a research note on Wednesday, March 11th. Separately, analysts at Brean Capital reiterated a “buy” rating on shares of Zogenix in a research note on Tuesday, January 20th.
Zogenix, Inc (NASDAQ:ZGNX) is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Its lead product candidate, Zohydro (hydrocodone bitartrate, formerly ZX002) is a 12-hour extended-release formulation of hydrocodone without acetaminophen for the treatment of chronic pain requiring opioid therapy.
